Lung Cancer Considered

In this episode of Lung Cancer Considered, host Dr. Narjust Florez conducts three mock molecular tumor boards with Dr. Misako Nagasaka and Dr. Biagio Ricciuti, live from the Targeted Therapies of Lung Cancer (TTLC) 2026 conference. The discussion addresses the question, “How do we get the right molecular answer, at the right time, for the right patient?”

Guests:

Misako Nagasaka, MD, PhD
Associate Clinical Professor
University of California, Irvine

Biagio Ricciuti, MD, PhD
Thoracic Medical Oncologist, Dana-Farber Cancer Institute
Faculty, Harvard School of Medicine

In this episode of Lung Cancer Considered, host Dr. Narjust Florez and guest Dr. Sam Rosner examine controversies around antibody-drug conjugates (ADCs) live from the 2026 Targeted Therapies of Lung Cancer (TTLC) conference.

Guest:

Sam Rosner, MD
Assistant Professor of Medicine, University of Maryland School of Medicine
Thoracic Medical Oncologist, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center

As part of IASLC’s ongoing series of podcasts in world languages, Dr. Alfredo Addeo moderates a Virtual Tumor Board discussion with Dr. Angela Botticella and Dr. Jean Yannis Perentes. The tumor board focuses on the management of resectable EGFR-mutant NSCLC.

Guests:

Angela Botticella, MD
Radiational Oncologist
Department of Radiation Oncology
Gustave Roussy

Jean Yannis Perentes, MD, PhD
Professor and Chief, Department of Thoracic Surgery
University Hospital of Lausanne CHUV

In this episode of Lung Cancer Considered, host Dr. Stephen Liu is joined by Dr. Sara Pilotto and Dr. Jonathan Riess for a virtual tumor board discussion on the management of metastatic EGFR exon 19 NSCLC . Using a complex case featuring discordant biomarker results and brain metastases, the panel explores first-line treatment strategies including osimertinib monotherapy, FLAURA2 (osimertinib plus chemotherapy), and MARIPOSA (amivantamab plus lazertinib), as well as sequencing at progression, re-biopsy, CNS considerations, and the evolving role of local consolidation and clinical trials.

In this episode of Lung Cancer Considered, host Dr. Narjust Florez explores controversies in managing lung cancer patients with comorbidities – those often underrepresented in clinical trials – with Dr. Hina Khan and Dr. Corey Langer, live from the Targeted Therapies of Lung Cancer (TTLC) 2026 conference. The discussion examines treatment decision-making in patients with ECOG performance status 2, renal dysfunction, advanced age, and complex comorbid conditions, emphasizing careful phenotyping, geriatric assessment, and individualized risk–benefit evaluation. The episode also highlights the balance between efficacy, toxicity, quality of life, and patient goals when treating the patients most commonly seen in clinical practice.

Guests:
Hina Khan, MD
Thoracic Oncologist
Assistant Professor of Medicine
Warren Alpert Medical School, Brown University

Corey Langer, MD, FACP
Director, Thoracic Oncology, Abramson Cancer Center
Professor of Medicine , Perelman School of Medicine
University of Pennsylvania